Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or progressive advanced epithelial ovarian cancer following previous paclitaxel.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer|
|Study Start Date:||January 1997|
|Study Completion Date:||August 2001|
|Primary Completion Date:||August 2001 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Evaluate the activity of paclitaxel when administered on a weekly schedule to patients with advanced ovarian cancer who have failed paclitaxel on a 3 or 24 hour infusion schedule. II. Evaluate the toxic effects of paclitaxel when administered on a weekly schedule in this patient population. III. Correlate response with quality of life outcomes, including symptom distress, performance status, and global quality of life.
OUTLINE: This is a single center, open label study. Paclitaxel is administered intravenously every week as a 1 hour infusion. Patients receive prophylactic anti-allergy premedication prior to paclitaxel.
PROJECTED ACCRUAL: 25-30 patients accrued per year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002928
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Carol Aghajanian, MD||Memorial Sloan Kettering Cancer Center|